Machine Learning in Glomerular Diseases: Promise for Precision Medicine

Girish N. Nadkarni; Kumardeep Chaudhary; Steven G. Coca

doi:10.1053/j.ajkd.2019.04.011

Machine Learning in Glomerular Diseases: Promise for Precision Medicine

Girish N. Nadkarni, Kumardeep Chaudhary, Steven G. Coca

Research output: Contribution to journal › Editorial

9 Scopus citations

Original language	English
Pages (from-to)	290-292
Number of pages	3
Journal	American Journal of Kidney Diseases
Volume	74
Issue number	3
DOIs	https://doi.org/10.1053/j.ajkd.2019.04.011
State	Published - Sep 2019

Access to Document

10.1053/j.ajkd.2019.04.011

Cite this

@article{19e2ef994af94153bcbd162d5be58dfa,

title = "Machine Learning in Glomerular Diseases: Promise for Precision Medicine",

author = "Nadkarni, {Girish N.} and Kumardeep Chaudhary and Coca, {Steven G.}",

note = "Funding Information: Drs Nadkarni and Coca receive financial compensation as consultants and advisory board members for and own equity in and are scientific cofounders of RenalytixAI, Inc. Dr Coca has received consulting fees from Goldfinch Bio, CHF Solutions, Quark Biopharma, Janssen Pharmaceuticals, and Takeda Pharmaceuticals in the past 3 years. Dr Nadkarni has received operational funding from Goldfinch Bio and consulting fees from BioVie Inc and GLG Consulting in the past 3 years. Drs Nadkarni and Coca are former members of the advisory board of PulseData, received consulting fees for their services, and continue to hold equity interests in PulseData. The remaining author declares that he has no relevant financial interests. Funding Information: Girish N. Nadkarni, MD, MPH, Kumardeep Chaudhary, PhD, and Steven G. Coca, DO, MS. None. Drs Nadkarni and Coca receive financial compensation as consultants and advisory board members for and own equity in and are scientific cofounders of RenalytixAI, Inc. Dr Coca has received consulting fees from Goldfinch Bio, CHF Solutions, Quark Biopharma, Janssen Pharmaceuticals, and Takeda Pharmaceuticals in the past 3 years. Dr Nadkarni has received operational funding from Goldfinch Bio and consulting fees from BioVie Inc and GLG Consulting in the past 3 years. Drs Nadkarni and Coca are former members of the advisory board of PulseData, received consulting fees for their services, and continue to hold equity interests in PulseData. The remaining author declares that he has no relevant financial interests. Received April 1, 2019, in response to an invitation from the journal. Accepted April 11, 2019, after editorial review by an Associate Editor and a Deputy Editor.",

year = "2019",

month = sep,

doi = "10.1053/j.ajkd.2019.04.011",

language = "English",

volume = "74",

pages = "290--292",

journal = "American Journal of Kidney Diseases",

issn = "0272-6386",

publisher = "W.B. Saunders Ltd",

number = "3",

}

TY - JOUR

T1 - Machine Learning in Glomerular Diseases

T2 - Promise for Precision Medicine

AU - Nadkarni, Girish N.

AU - Chaudhary, Kumardeep

AU - Coca, Steven G.

N1 - Funding Information: Drs Nadkarni and Coca receive financial compensation as consultants and advisory board members for and own equity in and are scientific cofounders of RenalytixAI, Inc. Dr Coca has received consulting fees from Goldfinch Bio, CHF Solutions, Quark Biopharma, Janssen Pharmaceuticals, and Takeda Pharmaceuticals in the past 3 years. Dr Nadkarni has received operational funding from Goldfinch Bio and consulting fees from BioVie Inc and GLG Consulting in the past 3 years. Drs Nadkarni and Coca are former members of the advisory board of PulseData, received consulting fees for their services, and continue to hold equity interests in PulseData. The remaining author declares that he has no relevant financial interests. Funding Information: Girish N. Nadkarni, MD, MPH, Kumardeep Chaudhary, PhD, and Steven G. Coca, DO, MS. None. Drs Nadkarni and Coca receive financial compensation as consultants and advisory board members for and own equity in and are scientific cofounders of RenalytixAI, Inc. Dr Coca has received consulting fees from Goldfinch Bio, CHF Solutions, Quark Biopharma, Janssen Pharmaceuticals, and Takeda Pharmaceuticals in the past 3 years. Dr Nadkarni has received operational funding from Goldfinch Bio and consulting fees from BioVie Inc and GLG Consulting in the past 3 years. Drs Nadkarni and Coca are former members of the advisory board of PulseData, received consulting fees for their services, and continue to hold equity interests in PulseData. The remaining author declares that he has no relevant financial interests. Received April 1, 2019, in response to an invitation from the journal. Accepted April 11, 2019, after editorial review by an Associate Editor and a Deputy Editor.

PY - 2019/9

Y1 - 2019/9

UR - http://www.scopus.com/inward/record.url?scp=85067064361&partnerID=8YFLogxK

U2 - 10.1053/j.ajkd.2019.04.011

DO - 10.1053/j.ajkd.2019.04.011

M3 - Editorial

C2 - 31200978

AN - SCOPUS:85067064361

SN - 0272-6386

VL - 74

SP - 290

EP - 292

JO - American Journal of Kidney Diseases

JF - American Journal of Kidney Diseases

IS - 3

ER -